Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP001149

Drug Information
SynonymsNCGC00015004-03; CL-67772; EU-0100116; Ascendin; Defanyl; Spectrum4_001218; Moxadil; KBio2_006062; Spectrum5_001284; EINECS 237-867-1; NCGC00015004-06; NINDS_000236; Amoxapina [INN-Spanish]; KBio3_001874; Prestwick3_000102; Prestwick2_000102; Amoxan; SPBio_001150; Spectrum2_001245; CHEBI:2675; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-; Prestwick1_000102; Amoxapine (JP15/USP/INN); DivK1c_000236; IDI1_000236; Spectrum_000446; 2-Chloro-11-(1-piperazinyl)- dibenz[b,f][1,4]oxazepine; amoxapine; A-129; CL-67,772; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine; Amoxapine [USAN:BAN:INN:JAN]; 14028-44-5; BRN 0832057; NCGC00015004-10; C17H16ClN3O; MLS000069371; LS-61563; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; I06-0520; Desmethylloxapine; L001293; Amoxepine; HMS500L18; Amoxapinum [INN-Latin]; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; AC-5495; PDSP1_001609; KBio2_000926; SPECTRUM2300161; Asendin; HMS2093N08; KBioGR_001656; SMR000058416; D00228; HMS2089G10; Dibenzo[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; Asendin (TN); NCGC00023887-03; SAM002564189; Prestwick_503; KBioSS_000926; BSPBio_000084; AC1L1D2U; NCGC00023887-04; KBio1_000236; NCGC00015004-02; NCGC00023887-05; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; Spectrum3_001067; DB00543; HMS1568E06; BRD-K02265150-001-05-9; CID2170; Lopac-A-129; CPD000058416; BPBio1_000094; DIBENZ(b,f)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-; MolPort-003-666-768; SPBio_002023; PDSP2_001593; Demolox; UNII-R63VQ857OT; CAS-14028-44-5; KS-1197; Asendis; KBio2_003494; Amoxapinum; CHEMBL1113; CL 67772; Lopac0_000116; Amoxapina; NCGC00015004-01; Desmethylloxapin; BSPBio_002654; A129_SIGMA; Prestwick0_000102; NCGC00023887-06    
Trade NameAsendin; Asendis; Defanyl; Demolox; Moxadil    
IndicationDepressionApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntidepressants    
CAS NumberCAS 14028-44-5
PubChem Compound IDCID 2170.    
PubChem Substance IDSID 169147.    
SuperDrug ATC IDN06AA17;    
SuperDrug CAS ID014028445;    
TargetNorepinephrine reuptakeInhibitor[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072688 To Reference
Ref 2Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543